Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03796455 · ClinicalTrials.gov registry record · NA
Fish Oil and HMB Supplementation in COPD
A NA study, sponsored by Texas A&M University.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT03796455 is a NA study that has completed, run by Texas A&M University. The registered enrollment target is 54 participants.
The verdict
NCT03796455, a NA study, has completed, sponsored by Texas A&M University.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
In the present study, the role of chronic (10 weeks) intake of low dose (2g/day) of EPA+DHA in whole body protein metabolism, and functional performance and systemic inflammation will be examined, and whether adding either HMB at 3.0 g/d to the low dose of EPA+DHA (2.0 g/d) will enhance these effects even more.
Interventions
- DIETARY_SUPPLEMENT Capsule + Powder supplementation
- OTHER stable tracer infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2018-04-25 |
| Est. Completion | 2020-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03796455
The ClinicalTrials.gov registry entry for NCT03796455 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas A&M University, which has 95 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capsule + Powder supplementation is the first listed.
NCT03796455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03796455 about?
NCT03796455 is a clinical study titled "Fish Oil and HMB Supplementation in COPD". In the present study, the role of chronic (10 weeks) intake of low dose (2g/day) of EPA+DHA in whole body protein metabolism, and functional performance and systemic inflammation will be examined, and whether adding either HMB at 3.0 g/d to the low dose of EPA+DHA (2.0 g/d) will enhance these effect...
What is the current status of trial NCT03796455?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2018-04-25. Estimated completion is 2020-04-01.
What interventions are being tested in trial NCT03796455?
The interventions under investigation include: Capsule + Powder supplementation (DIETARY_SUPPLEMENT), stable tracer infusion (OTHER).
Who is sponsoring clinical trial NCT03796455?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.